Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis

Cancer Research

Volumn 76, Issue 22, 2016, Pages 6747-6759

  Xia, Tianli ^a   Konno, Hiroyasu ^a   Barber, Glen N ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP AMP SYNTHASE; DINUCLEOTIDE; DNA; INTERFERON; ONCOLYTIC VIRUS; REGULATOR PROTEIN; STING PROTEIN; SYNTHETASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE; DNA VIRUS; EPIGENETICS; GENE SILENCING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNE EVASION; INFECTION SENSITIVITY; LYSIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRAL ONCOLYSIS; VIRUS INFECTION; ANIMAL; IMMUNOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MELANOMA; MICE; ONCOLYTIC VIRUSES; SIGNAL TRANSDUCTION;

EID: 84995477297     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1404     Document Type: Article

References (36)

1. PDQ Adult Treatment Editorial Board. Melanoma treatment (PDQO®): Health Professional Version. In: PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute; 2002. [cited 2016 Apr 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK66034/.
2. Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, et al. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep 2015;64:591-6.
3. Saito Rde F, Tortelli TC Jr, Jacomassi MD, Otake AH, Chammas R. Emerging targets for combination therapy in melanomas. FEBS Lett 2015;589:3438-48.
4. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82.
5. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780-8.
6. Lawler SE, Chiocca EA. Oncolytic virus-mediated immunotherapy: a combinatorial approach for cancer treatment. J Clin Oncol 2015;33:2812-4.
7. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008;455:674-8.
8. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A 2012;109:19386-91.
9. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009;461:788-92.
10. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339:786-91.
11. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011;478:515-8.
12. Hornung V, Hartmann R, Ablasser A, Hopfner KP. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol 2014;14:521-8.
13. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014;41:830-42.
14. Ahn J, Konno H, Barber GN. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene 2015;34:5302-8.
15. Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep 2016;14:282-97.
16. Konno H, Konno K, Barber GN. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 2013;155:688-98.
17. Ahn J, Barber GN. Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Curr Opin Immunol 2014;31:121-6.
18. Jin L, Xu LG, Yang IV, Davidson EJ, Schwartz DA, Wurfel MM, et al. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun 2011;12:263-9.
19. Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng Kao C. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One 2013;8:e77846.
20. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
21. Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF, et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 2014;14:54.
22. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol 2013;754:3-29.
23. Yarbrough ML, Zhang K, Sakthivel R, Forst CV, Posner BA, Barber GN, et al. Primate-specific miR-576-3p sets host defense signalling threshold. Nat Commun 2014;5:4963.
24. Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther 2009;16:905-15.
25. Rowe J, Cen P. TroVax in colorectal cancer. Hum Vaccin Immunother 2014;10:3196-200.
26. Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014;54:289-96.
27. Ahn J, Ruiz P, Barber GN. Intrinsic self-DNA triggers inflammatorydisease dependent on STING. J Immunol 2014;193:4634-42.
28. Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate immunity: links and trade-offs. Trends Immunol 2014;35:429-35.
29. Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol 2014;49:116-39.
30. Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun 2014;5:5166.
31. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014;41:843-52.
32. Zhu Q, Man SM, Gurung P, Liu Z, Vogel P, Lamkanfi M, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol 2014;193:4779-82.
33. Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 2015;36:250-6.
34. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015;11:1018-30.
35. Kondo T, Kobayashi J, Saitoh T, Maruyama K, Ishii KJ, Barber GN, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A 2013;110:2969-74.
36. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74-88.